Ingelheim, Germany and Indianapolis, US, June 09, 2012 - Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results from a post-hoc analysis that showed linagliptin is associated with improvements in glucose levels and a significant reduction in urinary albumin-to-creatinine ratio (UACR) of 33% (p<0.05) from baseline in patients with T2D and at high risk of declining renal function (some degree of albuminuria at baseline). UACR is a measure of albuminuria in T2D patients with declining renal function. 1 Linagliptin is a once-daily tablet that is used along with diet and exercise either as monotherapy or in combination with other treatments, such as metformin or metformin + sulphonylurea, to improve glycaemic control in adults with T2D. 2
The post-hoc analysis included 227 T2D patients at high risk of declining renal function from four randomised, 24 week trials who were on stable treatment with one of two types of blood pressure medicines that are the standard treatment for diabetic renal disease – angiotensin-converting enzyme inhibitors (ACEs) or angiotensin receptor blockers (ARBs). 1 In addition to a reduction in glucose levels, as measured by a 0.71% change in haemoglobin A1c [HbA1c] versus placebo at 24 weeks, a 29% reduction in UACR was demonstrated with linagliptin versus placebo. 1 HbA1c is measured in patients with diabetes to provide an index of blood glucose control for the previous two to three months.